Allena Pharmaceuticals, Inc. Investments Change (Net)

Investments Change (Net) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Investments Change (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Investments Change (Net) for the quarter ending December 31, 2017 was $0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Investments Change (Net) decreased by -100.0%
  • Annual Investments Change (Net) for 2017 was $23.5 Million (a -199.21% decrease from previous year)
  • Twelve month Investments Change (Net) ending December 31, 2017 was $23.5 Million (a -20.48% decrease compared to previous quarter)
  • Twelve month trailing Investments Change (Net) decreased by -264.04% year-over-year
Trailing Investments Change (Net) for the last four month:
31 Dec '17 30 Sep '17 30 Jun '17 31 Mar '17
$23.5 Million $29.5 Million $-3.44 Million $-14.3 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Investments Change (Net) of Allena Pharmaceuticals, Inc.

Most recent Investments Change (Net)of ALNA including historical data for past 10 years.

Interactive Chart of Investments Change (Net) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Investments Change (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2017 $0.0 $3.25 $10.88 $9.35 $23.47
2016 $6.05 $-29.71 $-23.66
2015 $0.0

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.